Skip to content
June 23, 2022

Equity.Guru

Investment information for the new generation

Revive Therapeutics

The COVID-19 pandemic and variant friends are almost securely in our rear-view for another year and soon the beaches will be full of people and the papers will be…
Revive Therapeutics (RVV.C) provided an update on their psilocybin development programs today. “Revive is building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders….
Naturally occurring psychedelic compounds such as DMT in ayahuasca, psilocybin in magic mushrooms, salvinorum A found in the salvia divinorum mint species, mescaline from peyote cacti and the scolpolamine…
Last week, I was asked at least a dozen times by market professionals, “What sector do you like right now?” Normally that’s an easy question to ask as there’s…
Latest News Revive Therapeutics Ltd. (RVV.C) has provided an update for the Company’s U.S. Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy…
We’re closing in on three years now and it’s becoming hard to believe there was a market before COVID-19. We can barely remember it. Cannabis was a thing briefly,…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release.   If you’re not entirely sure what an ETF…
Revive Therapeutics (RVV.C) announced they are entering into an exclusive license agreement with Puerto Rico Science Technology and Research Trust (PRSTRT)  for the intellectual property titled ‘Biologically Active Ganoderma…
Revive Therapeutics (RVV.C) provided an update on their psychedelics development and clinical programs focused on psilocybin, which they are aiming to use to treat a number of disorders. Revive…